Novavax's NanoFlu Influenza Vaccine Phase 3 Trial Meets All

BEIJING (dpa-AFX) - Novavax Inc. (NVAX) said that a complete results from a pivotal phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M

Related Keywords

Beijing , China , Stanley Erck , Novavax Inc , Lancet Infectious , Chief Executive Officer , Fluzone Quadrivalent , பெய்ஜிங் , சீனா , ஸ்டான்லி ஏற்க்க் , தலைமை நிர்வாகி அதிகாரி , Novavax , Nanoflu , Influenza , Vaccine , Hase , Trial , Meets , Primary , Endpoints ,